Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Oragenics Inc (OGEN)

Oragenics Inc (OGEN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE Arca]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 2,385
  • Shares Outstanding, K 4,336
  • Annual Sales, $ 0 K
  • Annual Income, $ -9,840 K
  • EBIT $ -9 M
  • EBITDA $ -9 M
  • 60-Month Beta 1.21
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 0.29
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -8.66
  • Most Recent Earnings $-1.96 on 11/07/25
  • Next Earnings Date 05/08/26
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5038 +14.63%
on 03/31/26
1.1100 -47.97%
on 03/11/26
-0.2542 (-30.56%)
since 03/02/26
3-Month
0.5038 +14.63%
on 03/31/26
1.1100 -47.97%
on 03/11/26
-0.2575 (-30.84%)
since 01/02/26
52-Week
0.5038 +14.63%
on 03/31/26
9.6000 -93.98%
on 06/02/25
-5.4195 (-90.37%)
since 04/02/25

Most Recent Stories

More News
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation

SARASOTA, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal...

OGEN : 0.5798 (+5.42%)
Oragenics, Inc. Receives Audit Opinion with Going Concern Explanation

SARASOTA, Fla., March 25, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal...

OGEN : 0.5798 (+5.42%)
ORAGENICS FILES ANNUAL REPORT ON FORM 10-K

REPORTS YEAR OF STRATEGIC TRANSFORMATION AND CLINCIAL ADVANCEMENT SARASOTA, Fla., March 17, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company...

OGEN : 0.5798 (+5.42%)
ORAGENICS INITIATES PHASE IIA CLINICAL TRIAL SITE ACTIVATION

FIRST SITE INITIATION VISIT COMPLETED IN AUSTRALIA SARASOTA, Fla., March 12, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted...

OGEN : 0.5798 (+5.42%)
ORAGENICS EXPLORES EXPANSION OF CNS PLATFORM PURSUING ACQUISTION OF ASSETS IN BRAIN HEALTH, RECOVERY, AND NEUROPROTECTION

SARASOTA, Fla., March 11, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN), a clinical-stage biotechnology company pioneering brain-targeted therapeutics through proprietary intranasal...

OGEN : 0.5798 (+5.42%)
Oragenics Receives HREC Approval for Phase IIa Clinical Trial of ONP-002 as a Treatment for Concussion and Mild Traumatic Brain Injury in Australia

All required regulatory approvals secured for trial site onboarding and patient enrollment at three Australian sites Potential first and only pharmacological treatment for the most prominent neurological...

OGEN : 0.5798 (+5.42%)
Oragenics Targets Projected $9 Billion Market by Advancing First and Only Clinical-Stage Concussion and Mild Traumatic Brain Injury Therapy

Outlines clinical and growth catalysts for ONP-002 in concussion and mild traumatic brain injury (mTBI)  Fully prepared to initiate near-term clinical site onboarding and first patient dosing in...

OGEN : 0.5798 (+5.42%)
Oragenics Partners with DUCK FLATS Pharma to Support FDA IND Readiness and Clinical Trial Design for Concussion Program

Collaboration reinforces regulatory diligence, nonclinical strategy and clinical trial integrity for novel intranasal concussion therapy Traumatic brain injuries affect more Americans each year...

OGEN : 0.5798 (+5.42%)
Oragenics to Participate in SCOPE Summit 2026 Focused on Advancing Clinical Research and Patient Care

Management to Engage with Global Clinical Research Leaders Ahead of Phase 2a Trial of Concussion Treatment Sarasota, Fla., Feb. 02, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN)...

OGEN : 0.5798 (+5.42%)
Oragenics to Present at the 2026 Sequire Investor Summit in Puerto Rico

Sarasota, Fla., Jan. 14, 2026 (GLOBE NEWSWIRE) -- Oragenics, Inc. (NYSE American: OGEN) (“the “Company”) today announced that it will be presenting at the upcoming Sequire Investor Summit 2026....

OGEN : 0.5798 (+5.42%)

Business Summary

Oragenics Inc is a biotechnology company focused on the development and licensure of innovative products and technologies for improving human health.

See More

Key Turning Points

3rd Resistance Point 0.5987
2nd Resistance Point 0.5889
1st Resistance Point 0.5695
Last Price 0.5798
1st Support Level 0.5403
2nd Support Level 0.5305
3rd Support Level 0.5111

See More

52-Week High 9.6000
Fibonacci 61.8% 6.1253
Fibonacci 50% 5.0519
Fibonacci 38.2% 3.9785
Last Price 0.5798
52-Week Low 0.5038

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.